Article
Oncology
Aman Chauhan, Alexandre Prieur, Jill Kolesar, Susanne Arnold, Lea Payen, Younes Mahi, Berengere Vire, Madison Sands, B. Mark Evers, Dominique Joubert, Lowell Anthony
Summary: Current blood-based biomarkers for neuroendocrine neoplasms lack sensitivity and specificity. This study examined the potential of human circulating progastrin as a biomarker for neuroendocrine neoplasms. The results showed that levels of circulating progastrin were significantly higher in neuroendocrine neoplasms patients and demonstrated high sensitivity and specificity. Plasma circulating progastrin may be a diagnostic blood biomarker for both low- and high-grade neuroendocrine neoplasms, but further research is needed.
Article
Radiology, Nuclear Medicine & Medical Imaging
Hai-Yan Chen, Yao Pan, Jie-Yu Chen, Lu-lu Liu, Yong-Bo Yang, Kai Li, Ri-Sheng Yu, Guo-Liang Shao
Summary: This study aimed to identify quantitative CT features for distinguishing well-differentiated pancreatic neuroendocrine tumors (PNETs) from poorly differentiated pancreatic neuroendocrine carcinomas (PNECs). The results showed that arterial/portal absolute enhancements were independent predictors with good diagnostic accuracy for differentiating between PNETs and PNECs. Arterial lesion enhancement had the highest diagnostic performance.
EUROPEAN RADIOLOGY
(2022)
Review
Oncology
Jamie M. J. Weaver, Richard A. Hubner, Juan W. Valle, Mairead G. Mcnamara
Summary: Extra-pulmonary poorly differentiated neuroendocrine carcinoma is a rare and poorly understood tumor type. While there is limited evidence for its treatment, recent research has helped clarify the first-line chemotherapy choices. However, the lack of data continues to be a challenge in the second-line setting. A personalized approach and emerging translational approaches focused on mouse models and genomic profiling may guide future trial designs.
Article
Oncology
Sarah R. Kaslow, Gerardo A. Vitiello, Katherine Prendergast, Leena Hani, Steven M. Cohen, Christopher Wolfgang, Russell S. Berman, Ann Y. Lee, Camilo Correa-Gallego
Summary: This study assessed treatment patterns and outcomes for poorly differentiated pancreatic neuroendocrine carcinoma and found that surgical resection was strongly associated with improved overall survival.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Surgery
Lucas W. Thornblade, Susanne G. Warner, Laleh Melstrom, Philip H. G. Ituarte, Sue Chang, Daneng Li, Yuman Fong, Gagandeep Singh
Summary: By studying patients with non-metastatic poorly differentiated gastroenteropancreatic neuroendocrine neoplasms, it was found that surgical treatment confers a significant survival advantage over systemic therapy, with longer median survival time and higher 5-year overall survival rates.
Article
Oncology
Derek J. Erstad, Arvind Dasari, Melissa W. Taggart, Harmeet Kaur, Tsuyoshi Konishi, Brian K. Bednarski, George J. Chang
Summary: Rectal neuroendocrine carcinomas (rNECs) are poorly understood, with most patients being older Caucasian males and presenting with lymph node or distant metastases. Chemotherapy and surgery were used in some cases, but overall survival remains poor for these patients.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Endocrinology & Metabolism
Giovanni Centonze, Patrick Maisonneuve, Natalie Prinzi, Sara Pusceddu, Luca Albarello, Eleonora Pisa, Massimo Barberis, Alessandro Vanoli, Paola Spaggiari, Paola Bossi, Laura Cattaneo, Giovanna Sabella, Enrico Solcia, Stefano La Rosa, Federica Grillo, Giovanna Tagliabue, Aldo Scarpa, Mauro Papotti, Marco Volante, Alessandro Mangogna, Alessandro Del Gobbo, Stefano Ferrero, Luigi Rolli, Elisa Roca, Luisa Bercich, Mauro Benvenuti, Luca Messerini, Frediano Inzani, Giancarlo Pruneri, Adele Busico, Federica Perrone, Elena Tamborini, Alessio Pellegrinelli, Ketevani Kankava, Alfredo Berruti, Ugo Pastorino, Nicola Fazio, Fausto Sessa, Carlo Capella, Guido Rindi, Massimo Milione
Summary: This study analyzed a large series of neuroendocrine carcinomas (NECs) to validate previously identified prognostic factors and determine if additional parameters could be isolated. The most relevant predictors for prognosis were Ki-67 index, morphology, stage, and site. However, morphology was not a significant factor when Ki-67 was greater than or equal to 55%.
NEUROENDOCRINOLOGY
(2023)
Article
Pathology
Monika Vyas, Laura H. Tang, Natasha Rekhtman, David S. Klimstra
Summary: This study observed a decrease in Ki67 index and increased heterogeneity in treated high-grade neuroendocrine neoplasms, which may lead to misdiagnosis as low-grade tumors.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY
(2021)
Article
Medicine, General & Internal
Filippo Ricciardiello, Michela Falco, Giuseppe Tortoriello, Ferdinando Riccardi, Raul Pellini, Brigida Iorio, Giuseppe Russo, Giuseppe Longo, Ciro Coppola, Takashi Takeuchi, Anna Grimaldi, Marianna Abate, Marianna Scrima, Alessia Maria Cossu, Raffaele Addeo, Alessandro Ottaiano, Alfonso Scarpa, Amedeo Boscaino, Giovanni Motta, Michele Caraglia, Marco Bocchetti, Gabriella Misso
Summary: Laryngeal neuroendocrine carcinomas are rare and heterogeneous malignancies. A retrospective study of ten patients showed that miRNA study revealed a specific signature related to poorly differentiated tumors. These findings may improve diagnosis and treatment outcomes for this aggressive neoplasm.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Pathology
Irene Chen, Dongwei Zhang, Moises Velez, Sierra Kovar, Xiaoyan Liao
Summary: Gastrointestinal NECs are aggressive neoplasms, with INSM1, synaptophysin, and SATB2 being sensitive markers, although not specific to site or tumor type.
PATHOLOGY RESEARCH AND PRACTICE
(2021)
Article
Oncology
James C. Yao, Jonathan Strosberg, Nicola Fazio, Marianne E. Pavel, Emily Bergsland, Philippe Ruszniewski, Daniel M. Halperin, Daneng Li, Salvatore Tafuto, Nitya Raj, Davide Campana, Susumu Hijioka, Markus Raderer, Rosine Guimbaud, Pablo Gajate, Sara Pusceddu, Albert Reising, Evgeny Degtyarev, Mark Shilkrut, Simantini Eddy, Simron Singh
Summary: Spartalizumab, a humanized anti-PD-1 monoclonal antibody, showed limited efficacy in patients with well-differentiated neuroendocrine tumors and poorly differentiated neuroendocrine carcinomas. However, there were promising results in the thoracic cohort, indicating the need for further investigation. The most common adverse events related to spartalizumab were fatigue and nausea in the NET group, and elevated liver enzymes in the GEP-NEC group.
ENDOCRINE-RELATED CANCER
(2021)
Article
Medicine, General & Internal
Xuewen Wang, Yanbin Wu, Xuefeng Cao, Xingyuan Zhang, Yu Cheng, Lingqun Kong
Summary: Duodenal neuroendocrine tumors (d-NET) are rare tumors with clinical manifestations similar to other digestive tract tumors. Surgery is the only radical treatment method, with the preferred approach being active radical resection of the tumor.
Article
Oncology
Yuanxiang Lu, Wensen Li, Ge Liu, Yongbo Yang, Erwei Xiao, Senmao Mu, Yuqi Guo, Deyu Li, Guoyi Yan
Summary: A total of 110 differentially expressed genes (DEGs) were identified in DPC, enriching our understanding of the biology and pathogenesis underlying the disease. Five hub genes were screened out as potential therapeutic targets for DPC.
CANCER CELL INTERNATIONAL
(2021)
Article
Virology
Pierpaolo Zorzato, Mattia Zambon, Silvia Gori, Helena Frayle, Maria Teresa Gervasi, Annarosa Del Mistro
Summary: Cervical cancer is primarily caused by persistent infection with high-risk types of Papillomaviruses, with regular screening programs playing a key role in reducing incidence and mortality rates. A case of delayed diagnosis underscores the importance of adhering to recommended protocols and participating in cervical cancer screening programs.
Article
Multidisciplinary Sciences
Sun Mi Lee, Chang Ohk Sung
Summary: Poorly differentiated neuroendocrine carcinoma (NEC) of the colorectum is a rare subtype of colorectal cancer with poor prognosis and high rates of metastasis, showing high frequencies of BRAF and RB1 mutations.
SCIENTIFIC REPORTS
(2021)